Press Releases

Emergent BioSolutions to Acquire Cangene Corporation

...

Read More

Emergent BioSolutions’ Otlertuzumab (TRU-016) Shows Positive Results in Combination with Rituximab in People with CLL

...

Read More

Emergent BioSolutions Presents Positive Interim Phase 2 Data Evaluating Otlertuzumab (TRU-016) in Combination with Bendamustine in People with Relapsed Chronic Lymphocytic Leukemia

...

Read More

Emergent BioSolutions to Webcast Presentation at the 32nd Annual J.P. Morgan Healthcare Conference

...

Read More

Emergent BioSolutions Appoints A.B. Cruz III as Executive Vice President and General Counsel

...

Read More

Emergent BioSolutions to Webcast Its Participation at the 25th Annual Piper Jaffray Healthcare Conference

...

Read More

Emergent BioSolutions Reports Financial Results for Third Quarter and First Nine Months of 2013

...

Read More

Emergent BioSolutions Announces Acceptance of Otlertuzumab Abstracts for Presentation at 2013 American Society of Hematology Annual Meeting

...

Read More

Emergent BioSolutions Presents Preclinical Data on ES414, Its Lead Bispecific ADAPTIR Therapeutic for Prostate Cancer

...

Read More

Emergent BioSolutions Wins 2013 North American Maintenance Excellence Award

...

Read More

Emergent BioSolutions to Webcast Presentation at Credit Suisse 2013 Healthcare Conference

...

Read More

Emergent BioSolutions to Release Third Quarter 2013 Financial Results and Conduct a Conference Call on November 7, 2013

...

Read More